A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

MAPS is delighted to report an important milestone towards a randomized clinical trial at the Veterans Affairs (VA) Administration, where so many of our nation’s veterans are treated for PTSD. The Food & Drug Administration (FDA) has recently approved the first protocol submitted by MAPS in partnership with esteemed PTSD researcher Rachel Yehuda through the VA’s investigator-initiated research program. She and her team plan to conduct this trial at the VA pending institutional and regulatory approvals